Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933313 | 0.91 | P2RY12 (0.64) | P2RY12CYP2C9CYP3A4KDM4E | |
| SCHEMBL3208916 | 0.86 | P2RY12 (0.62) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4115267 | 0.84 | P2RY12 (0.55) | P2RY12CYP2C9CYP3A4KDM4EKMT2A | |
| SCHEMBL5221403 | 0.84 | L3MBTL1 (0.64) | P2RY12KDM4EKMT2AALDH1A1OPRK1 | |
| SCHEMBL4877982 | 0.83 | KDM4E (0.58) | P2RY12CYP2C9CYP3A4KDM4EKMT2A | |
| SCHEMBL3922081 | 0.82 | P2RY12 (0.55) | P2RY12CYP2C9CYP3A4KDM4E | |
| SCHEMBL4115190 | 0.81 | P2RY12 (0.70) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| Hydrochloric Acid SCHEMBL4105657 | 0.81 | P2RY12 (0.62) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL22115153 | 0.80 | P2RY12 (0.72) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4115398 | 0.80 | P2RY12 (0.61) | P2RY12CYP2C9CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP2C9 853/4885CYP3A4 801/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885CYP2C9 453/4885CYP3A4 324/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP2C9 96/4885CYP3A4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.